February 28 - March 2, 2025
Day 3
A commercial strategist provides insight into the CAMPs Institutional Investment and fundraising landscape. He will explain how private equity firms, investment bankers, hedge funds, venture capital and other investors are currently performing due diligence and modelling CAMPs investments. The session will explore what can be done improve their perceptions
We are delighted to invite you to the first public Town Hall meeting to discuss the regulatory, policy and legal framework of the impending LCD on coverage of CAMPs for hard-to-heal wounds.
This follows two previous invitation-only Town Hall meetings, sponsored by GR Consulting and held in SAWC spring and fall 2024, where Preeya Pinto and Juliet McBride, partners at the top law firm King & Spalding and experts in healthcare regulation, policy advocacy and reimbursement litigation, set out to provide clarity and address any misinformation about the new determination. The meetings played a critical role in improving understanding about this issue and in the development of industry-driven advocacy initiatives designed to educate CMS and other stakeholders.
To build on this, JWC and GR Consulting are collaborating to bring the Town Hall meeting to a wider audience. The 2025 CAMPs Summit Town Hall will be open to all CAMPs industry and health providers, giving them the opportunity to ask questions, get clarification and contribute to the debate. Preeya and Juliet, who are two of the most knowledgeable and well-connected people in the legal reimbursement arena, will be joined in the panel by moderator, Joe Rolley, and Dr Bill Tettelbach and Dr Dan Kapp. Don’t miss out on this unprecedented opportunity to gain access to this level of expertise on the key issue facing the CAMPs community.
Town Hall meeting attendees will also be able to give feedback and vote on a new advocacy initiative, designed to inform CMS on the potential impact of the new LCD on patients and propose a credible and workable alternative.
Six insightful 20-min presentations including a 10-min Q&A session, showcasing the latest evidence on CAMPs and adjunct therapies framed around the following themes:
• Research trials in progress: preliminary results
• Innovations in CAMPs technology: exploring modes of action
• CAMPs: your questions answered
In this two-hour session, senior medical or scientific officers from six companies will take it in turns to present preliminary results for high-level research trials currently in progress on CAMP and describe the mechanism of action for their most innovative products. Each talk will be followed by a 10-minute Q&A
In this concluding session of the Town Hall, attendees will debate and then vote on amendments to the draft proposal for CMS on the LCD, to ensure it reflects the collective view of the wound-care community on the best way forward.